Kathiawad Today

Dystrophic Epidermolysis Bullosa Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

 Breaking News
  • No posts were found

Dystrophic Epidermolysis Bullosa Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

October 03
19:45 2022
Dystrophic Epidermolysis Bullosa Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Dystrophic Epidermolysis Bullosa pipeline constitutes 15+ key companies continuously working towards developing 15+ Dystrophic Epidermolysis Bullosa treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Dystrophic Epidermolysis Bullosa Overview

Dystrophic epidermolysis bullosa, or Dystrophic epidermolysis bullosa, is an incurable, often fatal skin blistering condition caused by a lack of collagen protein in the skin. It is caused by mutations in the COL7A1 gene encoding type VII collagen, or COL7, a major component of anchoring fibrils which connect the epidermis to the underlying dermis and provide structural adhesion between these skin layers in a healthy individual. The lack of COL7 in Dystrophic epidermolysis bullosa patients causes blisters to occur in the dermis as a result of its separation from the epidermis. This makes the skin incredibly fragile, leading to blistering or skin loss at the slightest friction or perturbation. Dystrophic epidermolysis bullosa is both progressive and incredibly painful.

 

Dystrophic Epidermolysis Bullosa Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dystrophic Epidermolysis Bullosa Market. 

 

The Dystrophic Epidermolysis Bullosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Dystrophic Epidermolysis Bullosa Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Dystrophic Epidermolysis Bullosa treatment therapies with a considerable amount of success over the years. Dystrophic Epidermolysis Bullosa Key players such as – Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others, are developing therapies for the Dystrophic Epidermolysis Bullosa treatment 
  • Dystrophic Epidermolysis Bullosa Emerging therapies such as – BPM31510, HOLOGENE-17, AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others are expected to have a significant impact on the Dystrophic Epidermolysis Bullosa market in the coming years.   
  • In August 2020, Krystal Biotech initiated a Phase III Double Blinded, Placebo-Controlled, Efficacy and Safety Study of Beremagene Geperpavec (VYJUVEK) for the Treatment of Dystrophic Epidermolysis Bullosa (DEB).In the study, Thirty-one (31) participants with DEB, aged 6 months or older at time of consent are planned for this Phase III study
  • The FDA and the EMA have each granted VYJUVEKTM orphan drug designation for the treatment of DEB, and the FDA has granted VYJUVEKTM fast track designation and rare pediatric designation for the treatment of DEB. In addition, in 2019, the FDA granted Regenerative Medicine Advanced Therapy (“RMAT”) to VYJUVEKTM for thetreatment of DEB and the EMA granted PRIority MEdicines (“PRIME”), eligibility for VYJUVEKT 

 

Dystrophic Epidermolysis Bullosa Pipeline Therapeutics Assessment

  • Dystrophic Epidermolysis Bullosa Assessment by Product Type
  • Dystrophic Epidermolysis Bullosa By Stage and Product Type
  • Dystrophic Epidermolysis Bullosa Assessment by Route of Administration
  • Dystrophic Epidermolysis Bullosa By Stage and Route of Administration
  • Dystrophic Epidermolysis Bullosa Assessment by Molecule Type
  • Dystrophic Epidermolysis Bullosa by Stage and Molecule Type 

 

DelveInsight’s Dystrophic Epidermolysis Bullosa Report covers around 15+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Dystrophic Epidermolysis Bullosa Drugs Under Different Phases of Clinical Development Include: 

  • BPM31510: Berg Pharma
  • HOLOGENE-17: Holostem Terapie Avanzate
  • AGLE102: Aegle Therapeutics
  • RGN-137: RegeneRx Biopharmaceuticals
  • PTR-01: BridgeBio Pharma
  • INM-755: InMed Pharmaceuticals
  • Dabocemagene autoficel: Fibrocell Science
  • VYJUVEK: Krystal Biotech 

 

Dystrophic Epidermolysis Bullosa Pipeline Analysis:

 

The Dystrophic Epidermolysis Bullosa pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Dystrophic Epidermolysis Bullosa treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dystrophic Epidermolysis Bullosa Treatment.
  • Dystrophic Epidermolysis Bullosa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dystrophic Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dystrophic Epidermolysis Bullosa market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Dystrophic Epidermolysis Bullosa product details are provided in the report. Download the Dystrophic Epidermolysis Bullosa pipeline report to learn more about the emerging Dystrophic Epidermolysis Bullosa therapies

 

Dystrophic Epidermolysis Bullosa Pipeline Market Drivers

  • Improving Healthcare Infrastructure
  • Demand for New and Effective Drugs

 

Dystrophic Epidermolysis Bullosa Pipeline Market Barriers

  • Currently no cure for all types of dystrophic epidermolysis bullosa
  • Making a diagnosis for a genetic or rare disease is often challenging

 

Get a Free Sample PDF Report to know more about Dystrophic Epidermolysis Bullosa Pipeline Assessment

Scope of Dystrophic Epidermolysis Bullosa Pipeline Drug Insight    

  • Coverage: Global
  • Key Dystrophic Epidermolysis Bullosa Companies: Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others
  • Key Dystrophic Epidermolysis Bullosa Therapies: BPM31510, HOLOGENE-17, AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others
  • Dystrophic Epidermolysis Bullosa Therapeutic Assessment: Dystrophic Epidermolysis Bullosa current marketed and Dystrophic Epidermolysis Bullosa emerging therapies
  • Dystrophic Epidermolysis Bullosa Market Dynamics:  Dystrophic Epidermolysis Bullosa market drivers and Dystrophic Epidermolysis Bullosa market barriers 

 

Request for Sample PDF Report for Dystrophic Epidermolysis Bullosa Pipeline Assessment and clinical trials

 

Table of Contents

1

Dystrophic Epidermolysis Bullosa Report Introduction

2

Dystrophic Epidermolysis Bullosa Executive Summary

3

Dystrophic Epidermolysis Bullosa Overview

4

Dystrophic Epidermolysis Bullosa- Analytical Perspective In-depth Commercial Assessment

5

Dystrophic Epidermolysis Bullosa Pipeline Therapeutics

6

Dystrophic Epidermolysis Bullosa Late Stage Products (Phase II/III)

7

Dystrophic Epidermolysis Bullosa Mid Stage Products (Phase II)

8

Dystrophic Epidermolysis Bullosa Early Stage Products (Phase I)

9

Dystrophic Epidermolysis Bullosa Preclinical Stage Products

10

Dystrophic Epidermolysis Bullosa Therapeutics Assessment

11

Dystrophic Epidermolysis Bullosa Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Dystrophic Epidermolysis Bullosa Key Companies

14

Dystrophic Epidermolysis Bullosa Key Products

15

Dystrophic Epidermolysis Bullosa Unmet Needs

16 

Dystrophic Epidermolysis Bullosa Market Drivers and Barriers

17

Dystrophic Epidermolysis Bullosa Future Perspectives and Conclusion

18

Dystrophic Epidermolysis Bullosa Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Dystrophic Epidermolysis Bullosa drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories